Immunomodulation by Intravenous Immunoglobulin: Role of Regulatory T Cells

被引：60

作者：

Maddur, Mohan S. ^{[1
,2
,3
]}

Othy, Shivashankar ^{[1
,2
,3
]}

Hegde, Pushpa ^{[1
,2
,3
]}

Vani, Janakiraman ^{[1
,2
,3
]}

Lacroix-Desmazes, Sebastien ^{[1
,2
,3
]}

Bayry, Jagadeesh ^{[1
,2
,3
]}

Kaveri, Srini V. ^{[1
,2
,3
]}

机构：

[1] Univ Paris 06, Ctr Rech Cordeliers, Equipe Immunopathol & Therapeut Immunointervent 1, UMR S 872, F-75006 Paris, France

[2] Univ Paris 05, UMR S 872, F-75006 Paris, France

[3] INSERM, Unite 872, F-75006 Paris, France

来源：

JOURNAL OF CLINICAL IMMUNOLOGY | 2010年 / 30卷

关键词：

IVIG; intravenous immunoglobulin; regulatory T cells; autoimmune diseases; inflammation; immunomodulation; MONOCLONAL-ANTIBODY; MECHANISMS; THERAPY; CTLA-4; AUTOIMMUNITY; SUPPRESSION; TREGITOPES; TOLERANCE; DISEASES;

D O I：

10.1007/s10875-010-9394-5

中图分类号：

R392 [医学免疫学]; Q939.91 [免疫学];

学科分类号：

100102 ;

摘要：

An altered immune homeostasis as a result of deficiency or defective function of CD4(+)CD25(+)FoxP3(+) regulatory T cells (Tregs) is common in several autoimmune diseases. Hence, therapeutic strategies to render Tregs functionally competent are being investigated. Intravenous immunoglobulin (IVIG) is being increasingly used for the treatment of a wide range of autoimmune and inflammatory diseases. Recent studies have demonstrated that IVIG induces the expansion of Tregs and enhances their suppressive functions. These effects of IVIG on Tregs correlate with the beneficial effects of IVIG in patients with autoimmune diseases. Thus, modulation of Tregs by IVIG represents a novel mode of action that explains the therapeutic effects of IVIG in T cell-mediated autoimmune diseases. However, the molecular mechanisms involved in IVIG-mediated modulation of Tregs are unclear and need further investigation.

引用

页码：S4 / S8

页数：5

共 24 条

[11] CD4+ regulatory T cells require CTLA-4 for the maintenance of systemic tolerance
Friedline, Randall H.
Brown, David S.
Nguyen, Hai
Kornfeld, Hardy
Lee, JinHee
Zhang, Yi
Appleby, Mark
Der, Sandy D.
Kang, Joonsoo
Chambers, Cynthia A.
[J]. JOURNAL OF EXPERIMENTAL MEDICINE, 2009, 206 (02) : 421 - 434
[12] CD25+ CD4+ regulatory T cells in patients with Kawasaki disease
Furuno, K
Yuge, T
Kusuhara, K
Takada, H
Nishio, H
Khajoee, V
Ohno, T
Hara, T
[J]. JOURNAL OF PEDIATRICS, 2004, 145 (03) : 385 - 390
[13] Drug Insight: the use of intravenous immunoglobulin in neurology - therapeutic considerations and practical issues
Gold, Ralf
Stangel, Martin
Dalakas, Marinos C.
[J]. NATURE CLINICAL PRACTICE NEUROLOGY, 2007, 3 (01): : 36 - 44
[14] Natural and TGF-β-induced Foxp3+CD4+ CD25+ regulatory T cells are not mirror images of each other
Horwitz, David A.
Zheng, Song Guo
Gray, J. Dixon
[J]. TRENDS IN IMMUNOLOGY, 2008, 29 (09) : 429 - 435
[15] Advances in immunology: Immunomodulation of autoimmune and inflammatory diseases with intravenous immune globulin.
Kazatchkine, MD
Kaveri, SV
[J]. NEW ENGLAND JOURNAL OF MEDICINE, 2001, 345 (10) : 747 - 755
[16] Intravenous immunoglobulin therapy affects T regulatory cells by increasing their suppressive function
Kessel, Aharon
Ammuri, Hana
Peri, Regina
Pavlotzky, Elsa R.
Blank, Miri
Shoenfeld, Yehuda
Toubi, Elias
[J]. JOURNAL OF IMMUNOLOGY, 2007, 179 (08) : 5571 - 5575
[17] Natural regulatory T cells: mechanisms of suppression
Miyara, Makoto
Sakaguchi, Shimon
[J]. TRENDS IN MOLECULAR MEDICINE, 2007, 13 (03) : 108 - 116
[18] Anti-inflammatory actions of intravenous immunoglobulin
Nimmerjahn, Falk
Ravetch, Jeffrey V.
[J]. ANNUAL REVIEW OF IMMUNOLOGY, 2008, 26 : 513 - 533
[19] Foxp3+ natural regulatory T cells preferentially form aggregates on dendritic cells in vitro and actively inhibit their maturation
Onishi, Yasushi
Fehervari, Zoltan
Yamaguchi, Tomoyuki
Sakaguchi, Shimon
[J]. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 2008, 105 (29) : 10113 - 10118
[20] Regulatory T cells and immune tolerance
Sakaguchi, Shimon
Yamaguchi, Tomoyuki
Nomura, Takashi
Ono, Masahiro
[J]. CELL, 2008, 133 (05) : 775 - 787

← 1 2 3 →